Volume 19, Number 9—September 2013
Chikungunya Virus Infection, Brazzaville, Republic of Congo, 2011
Highlight and copy the desired format.
|EID||Mombouli J, Bitsindou P, Elion D, Grolla A, Feldmann H, Niama FR, et al. Chikungunya Virus Infection, Brazzaville, Republic of Congo, 2011. Emerg Infect Dis. 2013;19(9):1542-1543. https://dx.doi.org/10.3201/eid1909.130451|
|AMA||Mombouli J, Bitsindou P, Elion D, et al. Chikungunya Virus Infection, Brazzaville, Republic of Congo, 2011. Emerging Infectious Diseases. 2013;19(9):1542-1543. doi:10.3201/eid1909.130451.|
|APA||Mombouli, J., Bitsindou, P., Elion, D., Grolla, A., Feldmann, H., Niama, F. R....Munster, V. J. (2013). Chikungunya Virus Infection, Brazzaville, Republic of Congo, 2011. Emerging Infectious Diseases, 19(9), 1542-1543. https://dx.doi.org/10.3201/eid1909.130451.|
To the Editor: Chikungunya virus (CHIKV) is a positive single-stranded RNA virus within the genus Alphavirus, family Togaviridae (1–3). In humans, CHIKV infection has a rapid onset and is typically cleared in 5–7 days. Following transmission, CHIKV replicates in the skin and then disseminates to the liver and joints. The incubation period for CHIKV infection is 2–4 days. Signs and symptoms of infection include high fever, rigors, headache, photophobia, and a petechial or maculopapular rash, and most infected persons also report severe joint pain (2–4). CHIKV is transmitted through the bite of infected Aedes aegypti and Ae. albopictus mosquitoes. The current reemergence of CHIKV seems to be related to 1) CHIKV host switching from Ae. aegypti to Ae. albopictus mosquitoes, while retaining Ae. aegypti mosquitoes as a vector, and 2) introduction of Ae. albopictus mosquitoes, which were originally from Southeast Asia, into new areas of the world, including Africa. Severe epidemics of CHIKV infection have occurred in countries in the Indian Ocean region and Africa (1–3). We report an outbreak of CHIKV infection in Brazzaville, Republic of Congo, that was associated with the mosquito vectors Ae. albopictus and Ae. aegypti.
In June 2011, reports were received of an outbreak of a new drug-resistant form of malaria in southwest Brazzaville. Diagnostic capacity for detecting arboviruses, including CHIKV, by using molecular diagnostic assays was immediately implemented at the Laboratoire National de Santé Publique in Brazzaville. Blood samples were collected from 23 suspected case-patients, and serum samples were obtained and stored at 4°C. RNA from patients’ serum samples was extracted by using the QIAamp Viral RNA Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. To determine if CHIKV, yellow fever virus, dengue virus, or malarial parasites were present in the serum samples, we performed quantitative reverse transcription PCR with Lightcycler 480 RNA Master Hydrolysis Probes (Roche Diagnostics, Mannheim, Germany) on the SmartCycler platform (Cepheid, Sunnyvale, CA, USA) (5–7). A cycle threshold (Ct) cutoff value of <40 was considered positive. Primary testing focused on CHIKV, and genomic RNA was detected in 21 of 23 patient serum samples (Ct 17.55–37.91) (Table). Neither yellow fever nor dengue virus genomic RNA was detected in any patient samples. However, malaria parasite genetic material was detected in the 2 samples that were negative for CHIKV (Table).
To investigate the involvement and distribution of potential vector mosquito species, we initiated an entomological study in the Makélékélé and Mfilou districts of Brazzaville, the 2 areas associated with the CHIKV outbreak. Mosquitoes were collected at various places in the 2 districts during different hours of the day (Technical Appendix Table [PDF - 76 KB - 1 page]). Mosquitoes were separated by species, Ae. aegypti or Ae. albopictus, into 13 different pools. The pools were homogenized in lysis buffer (Buffer AVL; QIAGEN) by using sterile disposable tissue grinders, and RNA was extracted. We then analyzed the samples for the presence of CHIKV genomic RNA by following the procedures described above for the serum samples. All 13 mosquito pools were positive for CHIKV genomic RNA (Ct 23.5–34.63) (Technical Appendix Table [PDF - 76 KB - 1 page]).
Our study in Brazzaville identified CHIKV as the causative agent for the 2011 outbreak of febrile illness characterized by severe joint pain. In the affected Brazzaville communities, the illness had been named robot malaria because of its effects on posture and locomotion, effects that are typical of CHIKV infection. We also found that during the outbreak, CHIKV was present in Ae. aegypti and Ae. albopictus mosquitoes, suggesting that these mosquitoes played a role in dissemination and spread of the virus. These findings are in line with the increasing distribution of CHIKV and its vector, Ae. albopictus mosquitoes, in Africa.
Of note, the outbreak in the Republic of Congo seems to have been associated with Ae. aegypti and Ae. albopictus mosquitoes, whereas outbreaks of CHIKV infection in neighboring Gabon are predominantly associated with Ae. albopictus mosquitoes (8,9). Our study confirms the suspected presence of Ae. albopictus mosquitoes in the Republic of Congo. The identification of Ae. albopictus mosquitoes as a vector for CHIKV in remote areas in Gabon indicates that similar remote areas in the Republic of Congo could also be at risk during future outbreaks of CHIKV infection (8).
The availability of diagnostic capacity for arbovirus detection in sub-Saharan Africa is urgently needed for the deployment of potential intervention strategies. Improved surveillance and rapid identification of novel arbovirus–associated outbreaks would strengthen the potential for recognition of arbovirus-related diseases by health care providers and public health officials. In the absence of CHIKV-specific prophylactic or therapeutic control measures, the only current mitigation strategies are based on community outreach, which provides early alerts regarding outbreaks, and on control of the mosquito vectors (10).
This work was supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under the International Centers for Excellence in Research program.
- Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet. 2012;379:662–71 .
- Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol. 2010;8:491–500.
- Suhrbier A, Jaffar-Bandjee MC, Gasque P. Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol. 2012;8:420–9.
- Nkoghe D, Kassa RF, Caron M, Grard G, Mombo I, Bikié B, Clinical forms of chikungunya in Gabon, 2010. PLoS Negl Trop Dis. 2012;6:e1517. PMID: 22348166
- Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription–PCR. J Clin Microbiol. 2002;40:2323–30.
- Lee MA, Tan CH, Aw LT, Tang CS, Singh M, Lee SH, Real-time fluorescence-based PCR for detection of malaria parasites. J Clin Microbiol. 2002;40:4343–5.
- Smith DR, Lee JS, Jahrling J, Kulesh DA, Turell MJ, Groebner JL, Development of field-based real-time reverse transcription-polymerase chain reaction assays for detection of chikungunya and O'nyong-nyong viruses in mosquitoes. Am J Trop Med Hyg. 2009;81:679–84.
- Paupy C, Kassa Kassa F, Caron M, Nkoghé D, Leroy EM. A chikungunya outbreak associated with the vector Aedes albopictus in remote villages of Gabon. Vector Borne Zoonotic Dis. 2012;12:167–9.
- Caron M, Paupy C, Grard G, Becquart P, Mombo I, Nso BB, Recent introduction and rapid dissemination of chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis. 2012;55:e45–53.
- Kamgang B, Marcombe S, Chandre F, Nchoutpouen E, Nwane P, Etang J, Insecticide susceptibility of Aedes aegypti and Aedes albopictus in central Africa. Parasit Vectors. 2011;4:79.
- Table. Detection of virus genomic RNA in patient serum samples, Brazzaville, Republic of Congo, June 2011
Technical AppendixCite This Article
Please use the form below to submit correspondence to the authors or contact them at the following address:
Vincent J. Munster, Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: August 06, 2013
- Page last updated: August 06, 2013
- Page last reviewed: August 06, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)